Fitness7 months ago
Nivolumab/Cabozantinib Combination Displays Activity in Non-Clear Cell RCC
Treatment with the PD-1 inhibitor nivolumab (Opdivo) plus the TKI cabozantinib (Cometriq) demonstrated efficacy and the potential for sustained responses among patients with non-clear cell renal...
